Curative effect of the rivaroxaban and the low-molecular weight heparin anticoagulation in patients with active malignant tumors combined with venous thromboembolism
10.3969/j.issn.1672-8467.2018.01.009
- VernacularTitle:利伐沙班和低分子肝素用于部分实体恶性肿瘤合并静脉血栓栓塞症抗凝的疗效分析
- Author:
Yong-Gang WANG
1
;
Zhen-Yu SHI
;
Wei-Guo FU
;
Min ZHOU
;
Yong DING
Author Information
1. 复旦大学附属中山医院血管外科 上海200032
- Keywords:
venous thromboembolism;
rivaroxaban;
low-molecular weight heparin;
malignant tumor;
anticoagulation
- From:
Fudan University Journal of Medical Sciences
2018;45(1):57-61
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of rivaroxaban in contrast with lowmolecular weight heparin (LMWH) in patients with active malignant tumor combined with venous thromboembolism (VTE).Methods This study was a prospective case-control study.All cases were from Zhongshan Hospital,Fudan University between Jan.,2015 and Aug.,2016.They were treated with either rivaroxaban or LMWH for anticoagulation.Patients were followed up for 90 days to observe the treatment efficacy,recurrence and bleeding events.The total efficiency,recurrence events,bleeding events and adverse events were statistically analyzed.Results A total of 67 patients were enrolled in this study.Among them,37 cases aged 38-84 years old were assigned to LMWH group,of which 16 cases (43.2％) were male.Another 30 cases aged 45-88 years old were assigned to rivaroxaban group and 12 cases (40.0％) were male.There was no statistically significant difference between the two groups.The total effective rate (P =0.699),recurrence events (P =0.774),bleeding events (P =0.490) and adverse events (P =0.448) between the LMWH group and the rivaroxaban group had no significant difference.Conclusions Rivaroxaban and LMWH anticoagulation had similar safety and efficacy in patients with active malignant tumor combined with VTE.
